GIVAT SHMUEL, Israel--(BUSINESS WIRE)--March 22, 2006--GammaCan International Inc. (OTC BB:GCAN), a developer of immunotherapies for the treatment of cancer and other diseases, today announced that the Company met with the U.S. Food and Drug Administration (FDA) on March 1st, 2006 to discuss requirements for the filing of an Investigational New Drug (IND) application for VitiGam, the Company’s second generation investigational treatment for metastatic melanoma.
